Changes are happening - please bear with us while we update our site.

Changes are happening - please bear with us while we update our site. Click here to give us your advice and feedback.

Can Telix (ASX:TLX) shares set another record after HY21 results?

Telix Pharmaceuticals Ltd (ASX: TLX) shares continue its upward trajectory, jumping 6% today. Can Telix shares keep lifting the bar? 

Telix Pharmaceuticals Ltd (ASX: TLX) shares continue its upward trajectory, jumping 6% today. Can Telix shares keep lifting the bar? 

Telix is a radiopharmaceutical company established and listed on ASX in 2017. Wait, what does it do?

It is developing a portfolio of products that address unmet medical needs in oncology (cancer) and rare diseases.

Today’s strong share price movement comes on the back of a solid set of results in FY20.

TLX share price

Source: Rask Media TLX 2-year share price chart

HY21 on track

As with most biotech companies, Telix continues to record significant losses as a lot of capital is deployed to develop medical products.

Telix ended the half-year with a loss of $33.4 million.

However, Telix notes its made significant progress towards becoming a commercial stage, financially sustainable and revenue generating company.

Below is a snapshot of the achievements to date.

Source: TLX HY21 interim report

As you can see, the market is excited about Telix’s strong momentum in segments that present huge market opportunities.

The company estimates the total addressable market value for just illuccix to be around US$900 million.

The launch of illuccix will be subject to a decision by the US Food and Drug Administration agency on 23 September 2021.

Given the numerous advancements made, it’s no surprise that research and development costs jumped by 58% to $13.67 million relative to FY20.

My take

The optimism in Telix continues to grow as it continues to demonstrate traction in the development of a wide range of drug products.

It can be often enticing to join the ride, especially when the waves are high but this one is outside my circle of competence.

So, it’s not on my radar for shares to watch.

However, if you have advanced knowledge of the aforementioned science, Telix could prove to be a fruitful investment.

To learn more about Rask, I’d highly recommend signing up for free Rask account and accessing our full stock reports. Click this link to join for free and access all of our free analyst reports.

$50,000 per year in passive income from shares? Yes, please!

With interest rates UP, now could be one of the best times to start earning passive income from a portfolio. Imagine earning 4%, 5% — or more — in dividend passive income from the best shares, LICs, or ETFs… it’s like magic.

So how do the best investors do it?

Chief Investment Officer Owen Rask has just released his brand new passive income report. Owen has outlined 10 of his favourite ETFs and shares to watch, his rules for passive income investing, why he would buy ETFs before LICs and more.

You can INSTANTLY access Owen’s report for FREE by CLICKING HERE NOW and creating a 100% FREE Rask Account.

(Psst. By creating a free Rask account, you’ll also get access to 15+ online courses, 1,000+ podcasts, invites to events, a weekly value investing newsletter and more!)

Unsubscribe anytime. Read our TermsFinancial Services GuidePrivacy Policy. We’ll never sell your email address. Our company is Australian owned.

Information warning: The information on this website is published by The Rask Group Pty Ltd (ABN: 36 622 810 995) is limited to factual information or (at most) general financial advice only. That means, the information and advice does not take into account your objectives, financial situation or needs. It is not specific to you, your needs, goals or objectives. Because of that, you should consider if the advice is appropriate to you and your needs, before acting on the information. If you don’t know what your needs are, you should consult a trusted and licensed financial adviser who can provide you with personal financial product advice. In addition, you should obtain and read the product disclosure statement (PDS) before making a decision to acquire a financial product. Please read our Terms and Conditions and Financial Services Guide before using this website. The Rask Group Pty Ltd is a Corporate Authorised Representative (#1280930) of AFSL #383169.

At the time of publishing, the author of this article does not have a financial or commercial interest in any of the companies mentioned
Skip to content